Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Scientia Ventures is a venture capital firm founded in 2020 and based in New York, NY. The firm emerged from a rebranding of New Ventures Funds, which had been operational since before 2017. This transition marked a strategic shift in focus, particularly with the launch of their third fund in 2017. Scientia Ventures primarily invests in early to mid-stage technology companies that are innovating within the life sciences sector.
The firm has a strong emphasis on computational biology, digitization of medicine, digital therapies, and traditional drug development. Scientia Ventures is committed to identifying and commercializing breakthrough innovations in healthcare, leveraging its deep expertise in the field. The firm operates from its office located at One Liberty Plaza, 46th Floor, New York, NY 10006.
As of now, Scientia Ventures manages at least three funds, although specific fund sizes and total assets under management (AUM) have not been publicly disclosed. The firm has established a reputation for its strategic investments in companies that are at the forefront of healthcare innovation.
Scientia Ventures targets investments in the life sciences sector, specifically focusing on four key areas: computational biology and chemistry, digitization of medicine, digital therapeutics, and traditional drug development. The firm invests across various stages, including pre-seed, seed, seed+ (extension), Series A, and Series B. Their check sizes are tailored to the needs of early to mid-stage companies, although specific amounts are not disclosed.
The firm emphasizes building new companies around identified innovations and partnering with existing firms to accelerate growth and commercialization. Scientia Ventures seeks novel and unique innovations with significant breakthrough potential, aiming to support companies that are pushing the boundaries of healthcare technology. Their geographic focus is primarily on North America, aligning with their mission to drive advancements in the healthcare sector.
Scientia Ventures has built a notable portfolio that includes several prominent companies in the healthcare and biotechnology sectors. Key portfolio companies include:
Rory Riggs: General Partner and founding partner of Scientia Ventures, Rory has extensive experience in healthcare investments and has previously held leadership roles in significant healthcare companies.
Mark Finn: General Partner, Mark brings a wealth of knowledge in venture capital and has a strong background in healthcare technology investments.
Jonathan Finn, CFA: General Partner and founding partner, Jonathan has a solid track record in financial analysis and investment strategy within the healthcare sector.
Harry Glorikian: General Partner, Harry leads digital systems work and is recognized as an author and commentator on healthcare technology.
Richard Warburg: General Partner, Richard focuses on drug development initiatives and has significant experience in the life sciences industry.
John Dessouki: Principal, John plays a key role in sourcing and evaluating investment opportunities.
Dave Schippers: Director of Fund Operations, responsible for overseeing the operational aspects of the firm.
Daniel Goldman: General Counsel, providing legal guidance and support for the firm’s investments.
Reid Wiseman: Consultant, offering strategic insights and advice to the firm.
Joel Dudley: Advisor, with expertise in healthcare technology and innovation.
John Elder: Advisor, providing insights into market trends and investment opportunities.
Omino Gardezi: Advisor, contributing knowledge in healthcare investments.
Stanley Prusiner, M.D.: Advisor, a Nobel Prize winner with significant contributions to the field of medicine.
To pitch to Scientia Ventures, founders should use the preferred channel of their website or email. It is important to include a comprehensive deck that outlines the business model, team, and technology. While specific response time expectations are not disclosed, it is advisable to follow up if no response is received within a reasonable timeframe. Warm introductions are preferred but not mandatory.
In October 2020, Scientia Ventures rebranded from New Ventures Funds, reflecting a strategic shift in focus and the launch of their third fund. This rebranding was aimed at enhancing their ability to identify and commercialize novel healthcare solutions.
Notable portfolio companies such as Royalty Pharma and ADC Therapeutics have achieved significant milestones, including successful IPOs, which highlight the firm's effective investment strategy and the value of its portfolio.
As of 2023, there have been no publicly reported recent deal activities or fund raises, indicating a potential period of consolidation or strategic planning within the firm.
What are Scientia Ventures' investment criteria?
Scientia Ventures invests in early to mid-stage technology companies within the life sciences sector, focusing on computational biology, digitization of medicine, digital therapeutics, and traditional drug development. They seek novel innovations with significant breakthrough potential.
How can I apply or pitch to Scientia Ventures?
Founders can pitch their ideas through the firm’s website at www.scientiavc.com or by emailing info@scientiavc.com. It is advisable to include a detailed business plan and information about the team and technology.
What makes Scientia Ventures different from other VC firms?
Scientia Ventures distinguishes itself by its deep expertise in healthcare and technology, focusing on building new companies around identified innovations and partnering with existing firms to accelerate growth and commercialization.
What is the geographic scope of Scientia Ventures?
The firm primarily focuses on investments within North America, aligning with its mission to drive advancements in healthcare technology.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, Scientia Ventures invests across various stages, including pre-seed, seed, seed+ (extension), Series A, and Series B, tailoring amounts to the needs of the companies they support.
What kind of post-investment involvement does Scientia Ventures have?
Scientia Ventures adds value by leveraging its expertise to guide portfolio companies through growth phases, facilitating partnerships and commercialization of innovative products.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.